StockData
Boundless Bio, Inc. logo

Boundless Bio, Inc. (BOLD) income statement

BOLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$2.40−0.01 (-0.41%)

Close on Nov 18, 2026Market cap $54.60MP/E –Yield –

See a number that looks wrong?